Navigation Links
Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
Date:12/1/2009

iquid and Antibacterial and Anti-inflammatory Capsules from the Chinese SFDA. One of our key growth strategies is to further expand our portfolio," Dr. Guoqing Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc., commented. "These products further complement our product portfolio and create additional revenue opportunities for indications which we have not previously addressed. We will immediately leverage current distribution network and available production capacity to produce these two products."

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
2. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... ALLENTOWN, Pa. , May 21, 2013  Lehigh ... additional TRU-D SmartUVC TM devices, adding to its ... With seven devices taking up residence within the network, ... in the U.S. to proactively combat superbugs and provide ... Short for Total Room Ultraviolet Disinfector, TRU-D – the ...
(Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
Breaking Medicine Technology:Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
... VIEW, Calif., June 23 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... present,results of its Phase 2a clinical trial of ... at the 50th Annual Scientific Meeting of,the American ... Boston,Copley Place in Boston, MA. The oral platform ...
... data from,PAREXEL International Corporation (Nasdaq: PRXL ), ... new,industry-sponsored clinical trial initiations, or starts, surged another ... analysis shows that the,biopharmaceutical industry submitted 662 commercial ... clinical studies for drugs in,2007, up from the ...
Cached Medicine Technology:Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 3PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 4PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 5
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve the ... Creative Corridor region, is releasing results for its 2013 ... Thursday, May 23rd at 10:30 a.m. The survey ... , The survey is a critical component to the ... nurture and retain people of diverse backgrounds, cultures and ...
(Date:5/21/2013)... AURORA, Colo. (May 21, 2013) A paper recently ... and co-written by physicians and scientists at the ... important genetic risk factor for pulmonary fibrosis can be ... lung disease. , Researchers looked at a fairly common ... is a component of the mucous produced by the ...
(Date:5/21/2013)... and technological research So Paulo Research Foundation, FAPESP, based ... estimated in US$ 680 million to support 17 Research, ... up to eleven years, subject to continuation reviews on ... the 17 RIDCs will come from FAPESP and the ... infrastructure). Host institutions will participate in a portion of ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Today, Zane ... HSA and FSA accounts. Zane Benefits, which provides ... benefits, is the leader in defined contribution ... arrangements . , According to Zane Benefits’ website, the ... was signed into law in 2010 and impacts many ...
(Date:5/21/2013)... 2013 While North Carolina is synonymous ... travel guides. Brunswick Plantation & Golf Resort is synonymous ... access to 27 holes of "Top10" championship golf. ... Carolina, knowing the Top 10 from an ... the overwhelming task of selecting the course to play. ...
Breaking Medicine News(10 mins):Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2
... for diabetes and heart disease, such as high blood ... risk typical of obesity, but they represent only a ... long-term study. The results will be presented Saturday at ... "Some obese persons have a normal cardiovascular risk ...
... ... product line. , ... Germantown, WI (PRWEB) June 19, 2010 -- Ellsworth Adhesives announced today it ... Rapid Seal® line offers high-performance, flexible, chemical resistant sealants that are designed for a ...
... June 2010: Achieving disease remission in patients with ... of socio-economic importance including work productivity and quality ... EULAR 2010, the Annual Congress of the European ... Austrian findings are reported in addition to improvements ...
... ... dedication among healthcare professionals. This awards program salutes the individual health care ... the patients and family members they serve in every sector of the ... Press Club in Washington, D.C., on October 4, where the award winners ...
... for many with low risk disease, researchers find , ... prostate cancer that has a low risk of progression, ... a suitable treatment option, according to a large-scale study ... to treat localized prostate cancer is controversial because, especially ...
... ... Gynecologic Oncologist Mildred Ridgway, MD is now performing a new procedure at Baptist Medical ... Removing uterine fibroids is referred to as a myomectomy, or fibroidectomy. , ... Jackson, MS (Vocus) June 18, ...
Cached Medicine News:Health News:Certain obese people are not at high risk of heart disease, diabetes 2Health News:Ellsworth Adhesives Is Adding PRC Rapid Seal Product Line Offering 2Health News:Targeting disease remission has socio-economic benefits over low disease activity 2Health News:Targeting disease remission has socio-economic benefits over low disease activity 3Health News:Dorland Health People Awards Accepting Entries through Friday, June 25, 2010 2Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2Health News:GYN Oncologist Uses da Vinci Surgical Robot to Preserve Fertility 2
... Eyes enzymatic cleaner is a ... removes stubborn deposits in as ... eyes enzymatic cleaner contains an ... irritating film on soft contact ...
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Titanium. Straight shafts with curved lower tip. Upper tip fits into positioning hole while lower jaw stabilizes the lens. Flat smooth handle with dull finish. Most popular size or model....
Medicine Products: